Citi is maintaining its Buy rating and its $30 price target on Bristol-Myers Squibb BMY following the FDA's approval of the company's Nulogix.
In its report, Citi writes, “The FDA approved Nulogix (belatacept) for the prevention of kidney transplant rejection as a result of the company resolving manufacturing issues at its manufacturing facility in Manati, Puerto Rico. We view the Nulogic opportunity as small, but highly profitable. We model $350M in worldwide 2015E sales, slightly higher than consensus of ~$300M. With a very small sales force detailing the product, we expect operating margins by 2015E for Nulogix of at least 60%, significantly higher than the company average of ~29%. We estimate that the product could contribute $0.09 to EPS (4% of total) in 2015E. The resolution of the manufacturing issues also increases the probability of a favorable FDA action on the Orencia subcutaneous injectable filing, which has an FDA action date of August 4th, 2011.”
BMY closed yesterday at $27.42.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in